GlobeNewswire

Bavarian Nordic Announces that Janssen has Received Positive CHMP Opinion for its Investigational Preventative Ebola Vaccine Regimen

Share

COPENHAGEN, Denmark, May 29, 2020 – Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) announced today that its strategic partner Janssen Pharmaceutical Companies of Johnson & Johnson has received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) for its investigational Ebola vaccine regimen for the prevention of the Ebola Virus Disease caused by the Zaire ebolavirus species.

Two Marketing Authorisation Applications (MAAs) were submitted to the EMA in support of the vaccines in the two-dose regimen, which includes Ad26.ZEBOV as the first dose, based on Janssen’s proprietary AdVac® viral vector technology, and MVA-BN Filo as the second dose, based on Bavarian Nordic’s MVA-BN® technology, administered approximately eight weeks later. The goal of this two-dose approach is to induce long-term immunity against Ebola Virus Disease.

The regimen is specifically designed to support preventative vaccination in countries that are at risk of Ebola outbreaks, as well as for other at-risk groups such as healthcare workers, BSL4 lab workers, military deployed from other countries, airport staff and visitors to high-risk countries. Janssen is collaborating with the World Health Organization on vaccine pre-qualification to broaden access of its investigational Ebola vaccine regimen to those most in need and enable registration in African countries; European Commission (EC) approval of this regimen may help accelerate this process.

“The positive opinion issued by CHMP for the Ebola vaccine regimen brings us closer to the second European approval of a product based on our MVA-BN platform, validating a broader usage of the technology in the development of novel vaccines to address unmet medical needs,” said Paul Chaplin, President and CEO of Bavarian Nordic. “We congratulate Janssen on this milestone and applaud their accelerated efforts to bring forward this Ebola vaccine to help protect people at risk of Ebola and prevent future outbreaks.”

Pending the final approval by the European Commission of the MVA-BN Filo vaccine, Bavarian Nordic would be eligible to receive a milestone payment of USD 10 million under the license agreement with Janssen.

Background
Bavarian Nordic and Janssen entered an agreement in 2014, under which MVA-BN Filo was licensed to Janssen as part of their commitment to developing an Ebola vaccine regimen. Under the agreement, Bavarian Nordic also manufactured a significant amount of vaccines.

To date, approximately 60,000 people have been vaccinated with the Ebola vaccine regimen in clinical studies and vaccination initiatives. Janssen-sponsored Phase 1 studies have been reported in peer-reviewed journals including JAMA and the Journal of Infectious Diseases, and Phase 1, 2 and 3 data were recently presented at the 2019 European Congress of Clinical Microbiology & Infectious Disease (ECCMID). These studies indicate that the vaccine regimen is well tolerated, inducing robust and durable immune responses to the Zaire Ebolavirus strain. In May 2019, the WHO’s Strategic Advisory Group of Experts (SAGE) on immunization recommended the use of the Janssen investigational Ebola vaccine regimen as part of efforts to contain the DRC outbreak and more than 50,000 people in the DRC and Rwanda were vaccinated. 

About Bavarian Nordic
Bavarian Nordic is a fully integrated biotechnology company focused on the development, manufacture and commercialization of life-saving vaccines. We are a global leader in smallpox vaccines and have been a long-term supplier to the U.S. Strategic National Stockpile of a non-replicating smallpox vaccine, which has been approved by the FDA under the trade name JYNNEOS®, also for the protection against monkeypox. The vaccine is approved as a smallpox vaccine in Europe under the trade name IMVANEX® and in Canada under the trade name IMVAMUNE®. Our commercial product portfolio furthermore contains market-leading vaccines Rabipur®/RabAvert® against rabies and Encepur® against tick-borne encephalitis. Using our live virus vaccine platform technology, MVA-BN®, we have created a diverse portfolio of proprietary and partnered product candidates designed to save and improve lives by unlocking the power of the immune system, including an investigational Ebola vaccine, licensed to Janssen. For more information visit www.bavarian-nordic.com.

Forward-looking statements
This announcement includes forward-looking statements that involve risks, uncertainties and other factors, many of which are outside of our control, that could cause actual results to differ materially from the results discussed in the forward-looking statements. Forward-looking statements include statements concerning our plans, objectives, goals, future events, performance and/or other information that is not historical information. All such forward-looking statements are expressly qualified by these cautionary statements and any other cautionary statements which may accompany the forward-looking statements. We undertake no obligation to publicly update or revise forward-looking statements to reflect subsequent events or circumstances after the date made, except as required by law.

Contacts
Europe: Rolf Sass Sørensen, Vice President Investor Relations, Tel: +45 61 77 47 43
US: Graham Morrell, Paddock Circle Advisors, graham@paddockcircle.com, Tel: +1 781 686 9600

Company Announcement no. 33 / 2020

Attachment

About GlobeNewswire

GlobeNewswire
GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://globenewswire.com

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire

Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire

Volta Finance Limited: Net Asset Value as at 30 June 202010.7.2020 18:25:06 CESTPress release

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, IN WHOLE OR PART, IN OR INTO THE UNITED STATES ***** Guernsey, 10 July 2020 AXA IM has published the Volta Finance Limited (the “Company” or “Volta Finance” or “Volta”) monthly report for June. The full report is attached to this release and will be available on Volta’s website shortly (www.voltafinance.com). PERFORMANCE and PORTFOLIO ACTIVITY June delivered another month of strong performance after May and April, helping further to recover the mark-to-market impact of the COVID-19 pandemic. Accounting for the €0.10 per share dividend paid 16th of June, Volta’s NAV* total return performance in June was +6.9%. With the increased confidence around cash flows from underlying assets over the medium term, not only was the Company able to restore the dividend ordinarily payable in April but has further declared a dividend of €0.11 per share payable on 29th July 2020, which is a return to the Company’s original payment timetable. The monthly perfo

Agfa-Gevaert: Publication of a transparency notification – Regulated information10.7.2020 17:40:00 CESTPress release

(Article 14 of the law of May 2, 2007 on the disclosure of significant shareholdings) Mortsel, Belgium – July 10, 2020 - 5.40 p.m. CET According to Agfa-Gevaert NV’s bylaws, the threshold as from which a shareholding needs to be disclosed, has been set at 3%, 5% and a multiple of 5%. In conformity with the Law of May 2, 2007 regarding the disclosure of significant shareholdings in listed companies, Agfa-Gevaert (Euronext: AGFB) discloses the following declaration: On July 3, 2020, Classic Fund Management AG has announced that as per July 1, 2020, its stake in Agfa-Gevaert is less than 3%. Notifications of important shareholdings to be made according to the Law of May 2, 2007 or Agfa-Gevaert NV’s bylaws, should be sent to viviane.dictus@agfa.com Contact: Viviane Dictus Director Corporate Communications tel. ++32 (0) 3 444 7124 e-mail: viviane.dictus@agfa.com Attachment 20200710 Classic Fund UK

Mandalay Resources Corporation meddelar sina produktions- och försäljningsresultat för andra kvartalet 202010.7.2020 15:17:47 CESTPressemelding

TORONTO, July 10, 2020 (GLOBE NEWSWIRE) -- Mandalay Resources Corporation (”Mandalay” eller ”bolaget”) (TSX: MND, OTCQB: MNDJF) tillkännagav idag sina produktions- och försäljningsresultat för andra kvartalet 2020. Under andra kvartalet 2020 producerade Mandalay en konsoliderad mängd motsvarande 24 752 säljbara uns guldekvivalent och sålde 24 916 uns guldekvivalent. Mandalays President och Chief Executive Officer, Dominic Duffy förklarade, ”Båda verksamheterna har fortsatt sin starka start på året med förbättrade resultat från första till andra kvartalet vad gäller total mängd sålda uns guldekvivalent. Produktionsresultatet för andra kvartalet var bolagets bästa konsoliderade guldproduktion för ett enskilt kvartal sedan fjärde kvartalet 2017.” Duffy konstaterade vidare, ”Resultaten i Costerfield var fortsatt utmärkta från Youle-ådern, vars anläggning producerade 13 502 uns guldekvivalent. Antimonproduktionen hade ännu ett stabilt kvartal med 933 sålda ton, vilket var bolagets högsta mä

Volta Finance Limited : Director Declaration10.7.2020 15:09:22 CESTPress release

Volta FinanceLimited (VTA/VTAS) Director Resignation Guernsey, 10 July 2020 Volta Finance Limited (the “Company”) announces that Atosa Moini, a non-executive director of the Company and Chair of the Management Engagement Committee, has notified the Company of her intention to step down from her role on the Board and resign as a Director of the Company with effect from 31st July 2020. Ms Moini has been on the Board since 2017 and the Directors would like to express their gratitude to her for her valuable contribution during that period. For further information, please contact: Company Secretary and Administrator BNP Paribas Securities Services S.C.A, Guernsey Branch guernsey.bp2s.volta.cosec@bnpparibas.com +44 (0) 1481 750 853

Bergman & Beving AB: The Annual Report for 2019/2020 has been published10.7.2020 15:00:00 CESTPress release

Press release The Annual Report for 2019/2020 has been published Bergman & Beving’s Annual Report for the financial year 1 April 2019–31 March 2020 has been published on the company's website today where it can be downloaded as a PDF version. Stockholm, 10 July 2020 Bergman & Beving AB (publ) For further information, please contact: Peter Schön, CFO, phone no.: +46 70 339 89 99 This information is information that Bergman & Beving AB (publ) is obliged to make public pursuant to the Securities Markets Act. The information was submitted for publication at 3.00pm CET on 10 July 2020. Bergman & Beving owns and refines companies that develop and market strong brands for professional users in industry and construction, mainly in the Nordic region, the Baltic States and Poland. Bergman & Beving aims to enable successful product companies to take the next step and become leading brands in their categories. The Group currently has some 20 brands, about 1,000 employees and revenue of approximate

Bergman & Beving AB: Årsredovisning 2019/2020 offentliggjord10.7.2020 15:00:00 CESTPressemelding

Pressmeddelande Årsredovisning 2019/2020 offentliggjord Bergman & Bevings årsredovisning för räkenskapsåret 1 april 2019 – 31 mars 2020 har idag publicerats på bolagets hemsida där den kan laddas ner som PDF-version. Stockholm den 10 juli 2020 Bergman & Beving AB (publ) För ytterligare information kontakta: Peter Schön, CFO, telefon 070-339 89 99 Denna information är sådan information som Bergman & Beving AB (publ) är skyldigt att offentliggöra enligt lagen om värdepappersmarknaden. Informationen lämnades för offentliggörande den 10 juli 2020 kl. 15:00 CET. Bergman & Beving äger och förädlar bolag som utvecklar och marknadsför starka varumärken till professionella användare inom industri och bygg – främst i Norden, Baltikum och Polen. Bergman & Beving ska vara den plats där framgångsrika produktbolag kan ta nästa steg och bli ledande varumärken inom sina kategorier. Koncernen har idag runt 20 varumärken, cirka 1000 anställda och en omsättning på cirka 4 miljarder kronor. Bergman & Bevi